Structure Therapeutics (GPCR) Profit After Tax (2022 - 2026)

Structure Therapeutics' Profit After Tax history runs 5 years deep, the most recent figure standing at -$3.2 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 93.06% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at $44.2 million (up 140.79% YoY), while the FY2025 annual figure was $140000.0, up 100.11% from the prior year.
• Profit After Tax for Q1 2026 stood at -$3.2 million, down from $174.3 million in the prior quarter.
• The five-year high for Profit After Tax was $174.3 million in Q4 2025, with the low at -$88.8 million in Q4 2023.
• The 5-year median for Profit After Tax is -$23.3 million (2023), against an average of -$14.4 million.
• Peak annual rise in Profit After Tax reached 549.38% in 2025, while the deepest fall reached 2061.79% in 2025.
• Structure Therapeutics' Profit After Tax stood at $39.5 million in 2022, then tumbled by 324.95% to -$88.8 million in 2023, then soared by 56.3% to -$38.8 million in 2024, then jumped by 549.38% to $174.3 million in 2025, then sank by 101.86% to -$3.2 million in 2026.
• Business Quant data shows GPCR's Profit After Tax at -$3.2 million in Q1 2026, $174.3 million in Q4 2025, and -$65.2 million in Q3 2025.